Harvard Bioscience, Inc.
HBIO
$0.489
$0.01292.71%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 22.04% | -972.43% | 100.99% | -287.57% | -198.67% |
Total Depreciation and Amortization | -10.27% | -7.07% | -0.96% | 2.02% | 4.65% |
Total Amortization of Deferred Charges | 200.00% | 87.14% | 40.00% | 27.14% | 0.00% |
Total Other Non-Cash Items | -76.40% | 1,792.36% | -76.55% | 849.07% | -36.69% |
Change in Net Operating Assets | 276.74% | 105.62% | -124.82% | -85.29% | -1,801.20% |
Cash from Operations | 425.65% | 112.83% | -59.91% | -119.31% | -123.82% |
Capital Expenditure | 89.12% | 20.47% | 63.73% | -305.53% | -58.22% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -111.29% | -140.48% | 28.57% | -25.54% | 1,281.48% |
Cash from Investing | -150.87% | -203.56% | 56.08% | -177.06% | 173.28% |
Total Debt Issued | -- | -- | -100.00% | 225.00% | 205.00% |
Total Debt Repaid | 67.21% | 71.62% | 69.23% | 73.33% | 17.57% |
Issuance of Common Stock | -75.66% | -- | -21.84% | -- | -69.52% |
Repurchase of Common Stock | 100.00% | -59.57% | 75.00% | -- | 95.93% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -810.73% | -14.12% | 67.03% | 176.51% | 107.45% |
Foreign Exchange rate Adjustments | 15,700.00% | 324.50% | -98.36% | 290.72% | 123.53% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 1,015.94% | 5,235.71% | 56.39% | -48.72% | -138.69% |